ILLUSTRATION. China’s medical products regulator said on Thursday (25/2/2021) that it has approved two more Covid-19 vaccines for public use. REUTERS / Tingshu Wang
Source: Reuters | Editor: Barratut Taqiyyah Rafie
KONTAN.CO.ID – BEIJING. China’s medical products regulator said on Thursday (25/2/2021) that it has approved two more Covid-19 vaccines for public use. This agreement increases the number of domestically produced vaccines that can be used in China to four vaccines.
Launch Reuters, the two vaccines are made by CanSino Biologics Inc (CanSinoBIO) and the Wuhan Institute of Biological Products, an affiliate of the China National Pharmaceutical Group (Sinopharm).
They are joined by a vaccine from Sinovac Biotech approved earlier this month, and another from the Sinopharm unit in Beijing approved last year.
Prior to formal approval for wider public use by the National Medical Products Administration, millions of doses of the two Sinopharm vaccines and Sinovac injections had been administered in China’s vaccination program. These programs target specific groups of people who face a higher risk of infection.
Also Read: Sinovac’s first batch of COVID-19 vaccines arrives in Singapore
The CanSinoBIO vaccine has received the green light for use by military personnel.
So far, China has not approved the Covid-19 vaccine developed by Western drug manufacturers.
The four approved Chinese vaccines can be stored at normal freezer temperatures. This is a plus for underprivileged countries which may have difficulty storing vaccines from Pfizer and Moderna which require cold temperatures for long-term storage.
Also Read: The Philippines is the last country in Asean to receive a Covid-19 vaccination
<!–
